Table III.
Clinical information of healthy subjects, patients with cirrhosis and CC-HCC.
| Parameter | Healthy control (n=22) | Cirrhosis (n=101) | CC-HCC (n=56) |
|---|---|---|---|
| Age (years) | 63±9 | 64±9 | 63±8 |
| Gender (M/F) | 15/7 | 68/33 | 40/16 |
| Child-Pugh A/B/C | N/A | 38/32/31 | 15/23/18 |
| Etiology | |||
| Viral, n (%) | N/A | 51 (50.5) | 29 (51.8) |
| Alcoholic, n (%) | N/A | 19 (18.8) | 10 (17.9) |
| Autoimmune, n (%) | N/A | 11 (10.9) | 4 (7.1) |
| Others, n (%) | N/A | 20 (19.8) | 13 (23.2) |
| ALT (U/l) | 16±7 | 25±18b | 48±39a |
| ALP (U/l) | 68±19 | 103±45 | 125±62a |
| Albumin (g/l) | 43±6 | 33±8a | 31±8a |
| PT (s) | 10.9±0.8 | 15.0±3.1a | 14.5±3.0a |
| Clinical characteristics | |||
| Ascites | N/A | 58 (57.4) | 34 (60.7) |
| Spontaneous bacterial peritonitis | N/A | 13 (12.9) | 3 (5.4) |
| Hepatic encephalopathy | N/A | 24 (23.8) | 6 (19.7) |
| Medical history | |||
| Upper gastrointestinal hemorrhage | N/A | 51 (50.5)b | 18 (32.1) |
| Symptomatic treatment of medicine | N/A | 101 (100) | 56 (100) |
a
P<0.05, patients with cirrhosis (or CC-HCC) vs. healthy controls
b
P<0.05, patients with cirrhosis vs. patients with CC-HCC. ALT, alanine transaminase; ALP, alkaline phosphatase; CC-HCC, cirrhosis complicated with hepatocellular carcinoma; F, female; M, male; N/A, not applicable; PT, prothrombin time.